Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female 50 years of age or older; post-menopausal (≥ 12 Mo/ from last menstruation)~* Documented left ventricular ejection fraction (LVEF) of 20-40% within 90 days prior to the baseline visit~* History of HF for more than 90 days and a diagnosis of symptomatic HF (Class III NYHA) for at least 30 days prior to the baseline visit~* Ambulatory (i.e., able to walk without assistance of another person or device such as cane or walker)~Exclusion Criteria:~* Neuromuscular or rheumatologic conditions that limit the to their ability to improve walking distance~* Pulmonary edema or multiorgan failure or cardiogenic shock within 30 days prior to the baseline visit~* Congenital heart disease, infiltrative myocardial disease~* Unstable angina or myocardial infarction within 30 days prior to the baseline visit~* Undiagnosed abnormal genital bleeding~* History of breast cancer, breast surgery, or breast disease contraindicating estrogen/hormone therapy~* Polycystic ovary syndrome or any other condition known to be adversely affected by testosterone treatment~* Resting heart rate \> 120 bpm~* Systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 100 mmHg~* Known or suspected hypersensitivity or allergy to any adhesive or to any of the components of the testosterone transdermal system (TTS)~* Use of SERMS, SARMS, SPRMs, tibolone, testosterone, estrogen, progesterone agonists and antagonists or taking any prescription and over the counter medications/ nutraceuticals (eg, phyto-estrogens) that may have anabolic or steroid hormonal effects within 30 days prior to the baseline visit~* Use of marketed or investigational oral, sub-lingual, topical, transdermal injectable, or vaginal androgen therapy including dehydroepiandrosterone (DHEA) at any time within 3 months prior to the baseline visit~* Use of systemic corticosteroids within 30 days prior to the baseline visit (acute use for fewer than 7 days is acceptable)

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): placebo patch
- 300 µg/day testosterone (Type: EXPERIMENTAL): 300 micrograms/day transdermal testosterone patch
- 450 µg/day testosterone (Type: EXPERIMENTAL): 450 micrograms/day transdermal testosterone patch

Based on this trial design, predict the completion outcome and termination type (if applicable).